Direct progesterone receptor and indirect androgen receptor interactions with the kallikrein-related peptidase 4 gene promoter in breast and prostate cancer

Molecular Cancer Research

Volumn 7, Issue 1, 2009, Pages 129-141

  Lai, John ^a   Myers, Stephen A ^a   Lawrence, Mitchell G ^a   Odorico, Dimitri M ^a   Clements, Judith A ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; HORMONE; KALLIKREIN; KALLIKREIN 4; KALLIKREIN 6; LUCIFERASE; PARATHION; PROGESTERONE RECEPTOR; SERINE PROTEINASE; STEROID HORMONE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CHROMATIN; CONTROLLED STUDY; EXON; GEL MOBILITY SHIFT ASSAY; GENE CONTROL; GENE EXPRESSION; HORMONAL REGULATION; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN VARIANT; RECEPTOR BINDING; TRANSCRIPTION INITIATION SITE;

BASE SEQUENCE; BREAST NEOPLASMS; CHROMOSOME MAPPING; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KALLIKREINS; MALE; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TRANSFECTION;

EID: 58649120306     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0218     Document Type: Article

References (54)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 2006;56:168-83.
3. McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 2004;119:174-86.
4. Beresford MJ, Ravichandran D, Makris A. Neoadjuvant endocrine therapy in breast cancer. Cancer Treat Rev 2007;33:48 -57.
5. Gillatt D. Antiandrogen treatments in locally advanced prostate cancer: are they all the same? J Cancer Res Clin Oncol 2006;132 Suppl 1:S17-26.
6. Clements JA, Willemsen NM, Myers SA, Dong Y. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004;41:265-312.
7. Paliouras M, Borgono C, Diamandis EP. Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007;249:61 -79.
8. Yousef GM, Obiezu CV, Luo LY, Black MH, Diamandis EP. Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. Cancer Res 1999;59:4252 -6.
9. Hu JC, Zhang C, Sun X, et al. Characterization of the mouse and human PRSS17 genes, their relationship to other serine proteases, and the expression of PRSS17 in developing mouse incisors. Gene 2000;251:1 -8.
10. Nelson PS, Gan L, Ferguson C, et al. Molecular cloning and characterization of prostase, an androgen-regulated serine protease withprostate-restricted expression. Proc Natl Acad Sci U S A 1999;96:3114-9.
11. Stephenson SA, Verity K, Ashworth LK, Clements JA. Localization ofa new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4. J Biol Chem 1999;274:23210-4.
12. Hu JC, Sun X, Zhang C, Liu S, Bartlett JD, Simmer JP. Enamelysin and kallikrein-4 mRNA expression in developing mouse molars. Eur J Oral Sci 2002; 110:307-15.
13. Takayama TK, McMullen BA, Nelson PS, Matsumura M, Fujikawa K. Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 2001;40:15341 -8.
14. Matsumura M, Bhatt AS, Andress D, et al. Substrates ofthe prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate 2005;62:1 -13.
15. Korkmaz KS, Korkmaz CG, Pretlow TG, Saatcioglu F. Distinctly different gene structure of KLK4/KLK-L1/prostase/ARM1 compared withother members of the kallikrein family: intracellular localization, alternative cDNA forms, and Regulation by multiple hormones. DNA Cell Biol 2001;20:435-45.
16. Yousef GM, Diamandis EP. The new kallikrein-like gene, KLK-L2. Molecular characterization, mapping, tissue expression, and hormonal regulation. J Biol Chem 1999;274:37511 -6.
17. Dong Y, Kaushal A, Bui L, et al. Human kallikrein 4 (KLK4) is highly xpressed in serous ovarian carcinomas. Clin Cancer Res 2001;7:2363 -71.
18. Myers SA, Clements JA. Kallikrein 4 (KLK4), a new member of the human kallikrein gene family is up-regulated by estrogen and progesterone in the human endometrial cancer cell line, KLE. J Clin Endocrinol Metab 2001;86:2323 -6.
19. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002;9:601 -10.
20. Jia L, Coetzee GA. Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus. Cancer Res 2005;65:8003 -8.
21. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgen -regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 1997;11:148-61.
22. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 1996; 271:6379-88.
23. Mitchell SH, Murtha PE, Zhang S, Zhu W, Young CY. An androgen response element mediates LNCaP cell dependent androgen induction of the hK2 gene. Mol Cell Endocrinol 2000;168:89-99.
24. Zhang J, Zhang S, Murtha PE, Zhu W, Hou SS, Young CY. Identification of two novel cis -elements in the promoter of the prostate-specific antigen gene that are required to enhance androgen receptor-mediated transactivation. Nucleic Acids Res 1997;25:3143 -50.
25. Zhang S, Murtha PE, Young CY. Defining a functional androgen responsive element in the 5′ far upstream flanking region of the prostate-specific antigen gene. Biochem Biophys Res Commun 1997;231:784-8.
26. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 1991;5:1921 -30.
27. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR. Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 1996;271:7043 -51.
28. Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004;2:257 -80.
29. Dong Y, Bui LT, Odorico DM, et al. Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms. Endocr Relat Cancer 2005;12:875-89.
30. Obiezu CV, Soosaipillai A, Jung K, et al. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohis-tochemistry. Clin Chem 2002;48:1232 -40.
31. Veveris-Lowe TL, Lawrence MG, Collard RL, et al. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer 2005;12:631 -43.
32. Yamakoshi Y, Hu JC, Fukae M, Yamakoshi F, Simmer JP. How do enamelysin and kallikrein 4 process the 32-kDa enamelin? Eur J Oral Sci 2006; 114 Suppl 1:45-51; discussion 93-5, 379-80.
33. Ryu O, Hu JC, Yamakoshi Y, et al. Porcine kallikrein-4 activation, glycosylation, activity, and expression in prokaryotic and eukaryotic hosts. Eur J Oral Sci 2002;110:358 -65.
34. Prezas P, Arlt MJ, Viktorov P, et al. Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. Biol Chem 2006;387:807 -11.
35. Simmer JP, Bartlett JD. Kallikrein 4 is a secreted protein. Cancer Res 2004; 64:8481 -2; author reply 2-3.
36. Xi Z, Klokk TI, Korkmaz K, et al. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res 2004;64:2365 -70.
37. Suzuki Y, Tsunoda T, Sese J, et al. Identification and characterization of the potential promoterregions of 1031 kinds of human genes. Genome Res 2001;11: 677 -84.
38. Ham J, Thomson A, Needham M, Webb P, Parker M. Characterization of response elements for androgens, glucocorticoids and progestins in mouse mammary tumour virus. Nucleic Acids Res 1988;16:5263 -76.
39. Schoenmakers E, Alen P, Verrijdt G, et al. Differential DNA binding by the androgen and glucocorticoid receptors involves the second Zn -finger and a C -terminal extension of the DNA-binding domains. Biochem J 1999;341: 515-21.
40. Verrijdt G, Schoenmakers E, Alen P, et al. Androgen specificity ofa response unit upstream of the human secretory component gene is mediated by differential receptor binding to an essential androgen response element. Mol Endocrinol 1999;13:1558 -70.
41. Verrijdt G, Schoenmakers E, Haelens A, et al. Change of specificity mutations in androgen-selective enhancers. Evidence for a role of differential DNA binding by the androgen receptor. J Biol Chem 2000;275:12298 -305.
42. Schoenmakers E, Verrijdt G, Peeters B, Verhoeven G, Rombauts W, Claessens F. Differences in DNA binding characteristics of the androgen and glucocorticoid receptors can determine hormone-specific responses. J Biol Chem 2000;275:12290-7.
43. Haelens A, Verrijdt G, Callewaert L, Peeters B, Rombauts W, Claessens F. Androgen -receptor -specific DNA binding to an element in the first exon of the human secretory component gene. Biochem J 2001;353:611 -20.
44. Schauwaers K, De Gendt K, Saunders PT, et al. Loss of androgen receptor binding to selective androgen response elements causes a reproductive phenotype in a knockin mouse model. Proc Natl Acad Sci U S A 2007;104:4961 -6.
45. Lai J, Kedda MA, Hinze K, et al. PSA/KLK3 AREI promoterpolymorphism alters androgen receptor binding and is associated withprostate cancer susceptibility. Carcinogenesis 2007;28:1032 -9.
46. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev 2001;81:1269 -304.
47. Nelson KK, Subbaram S, Connor KM, et al. Redox-dependent matrix metalloproteinase-1 expression is regulated by JNK through Ets and AP-1 promoter motifs. J Biol Chem 2006;281:14100-10.
48. Gonzalez MI, Robins DM. Oct-1 preferentially interacts withandrogen receptor in a DNA-dependent manner that facilitates recruitment of SRC-1. J Biol Chem 2001;276:6420-8.
49. Moore MR, Zhou JL, Blankenship KA, Strobl JS, Edwards DP, Gentry RN. A sequence in the 5′ flanking region confers progestin responsiveness on the human c-myc gene. J Steroid Biochem Mol Biol 1997;62:243 -52.
50. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000;103: 843 -52.
51. Jin RJ, Wang Y, Masumori N, et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 2004;64:5489 -95.
52. Quandt K, FrechK, Karas H, Wingender E, Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995;23:4878 -84.
53. Prestridge DS. Computersoftware foreukaryotic promoteranalysis. Methods Mol Biol 2000;130:265 -95.
54. FrithMC, Hansen U, Weng Z. Detection of cis-element clusters in higher eukaryotic DNA. Bioinformatics 2001;17:878 -89.